PT  - JOURNAL ARTICLE
AU  - Sharma, Abhinav
AU  - Lövgren, Sandy Kang
AU  - Eriksson, Kajsa Ledesma
AU  - Wang, Yinxi
AU  - Robertson, Stephanie
AU  - Hartman, Johan
AU  - Rantalainen, Mattias
TI  - Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images
AID  - 10.1101/2023.10.10.23296761
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2023.10.10.23296761
4099  - http://medrxiv.org/content/early/2024/07/02/2023.10.10.23296761.short
4100  - http://medrxiv.org/content/early/2024/07/02/2023.10.10.23296761.full
AB  - Background Stratipath Breast is a CE-IVD marked artificial intelligence-based solution for prognostic risk stratification of breast cancer patients into high- and low-risk groups, using haematoxylin and eosin (H&E)-stained histopathology whole slide images (WSIs). In this validation study, we assessed the prognostic performance of Stratipath Breast in two independent breast cancer cohorts.Methods This retrospective multi-site validation study included 2719 patients with primary breast cancer from two Swedish hospitals. The Stratipath Breast tool was applied to stratify patients based on digitised WSIs of the diagnostic H&E-stained tissue sections from surgically resected tumours. The prognostic performance was evaluated using time-to-event analysis by multivariable Cox Proportional Hazards analysis with progression-free survival (PFS) as the primary endpoint.Results In the clinically relevant oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative patient subgroup, the estimated hazard ratio (HR) associated with PFS between low- and high-risk groups was 2.76 (95% CI: 1.63-4.66, p-value < 0.001) after adjusting for established risk factors. In the ER+/HER2-Nottingham histological grade (NHG) 2 subgroup, the HR was 2.20 (95% CI: 1.22-3.98, p-value = 0.009) between low- and high-risk groups.Conclusion The results indicate an independent prognostic value of Stratipath Breast among all breast cancer patients, as well as in the clinically relevant ER+/HER2-subgroup and the NHG2/ER+/HER2-subgroup. Improved risk stratification of intermediate-risk ER+/HER2-breast cancers provides information relevant for treatment decisions of adjuvant chemotherapy and has the potential to reduce both under- and overtreatment. Image-based risk stratification provides the added benefit of short lead times and substantially lower cost compared to molecular diagnostics and therefore has the potential to reach broader patient groups.Competing Interest StatementJH has obtained speaker's honoraria or advisory board remunerations from Roche, Novartis, AstraZeneca, Pfizer, Eli Lilly, MSD and Gilead, and has received institutional research support from Cepheid, Novartis, Roche and AstraZeneca. MR and JH are co-founders and shareholders of Stratipath AB. SR is an employee at Stratipath AB and holds employee stock options. All other authors have declared no conflicts of interest.Funding StatementThis work was supported by funding from the Swedish Research Council, Swedish Cancer Society, Karolinska Institutet, ERA PerMed (ERAPERMED2019-224-ABCAP), VINNOVA and SweLIFE (SwAIPP project), MedTechLabs, Swedish e-science Research Centre (SeRC) - eCPC, Stockholm Region, Stockholm Cancer Society and Swedish Breast Cancer Association.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has approval from the Swedish Ethical Review Authority (2017/2106-31, with amendments 2018/1462-32 and 2019-02336). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData cannot be made public due to local legislation since it contains sensitive patient data. H&EHaematoxylin & EosinWSIWhole Slide ImageEROestrogen ReceptorHER2Human Epidermal Growth Factor Receptor 2HRHazard RatioPFSProgression-Free SurvivalNHGNottingham Histological GradeRSRisk ScoreATACArimidex, Tamoxifen Alone or in CombinationRORRisk Of RecurrenceABCSG-8Austrian Breast and Colorectal Study Group-8GGIGenomic Grade IndexAIArtificial IntelligenceKMKaplan-MeierIHCImmunohistochemistryCIConfidence IntervalPHProportional Hazard